Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (IMPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03378297
Recruitment Status : Recruiting
First Posted : December 19, 2017
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Haukeland University Hospital

Brief Summary:

The study will be conducted in women with advanced (stage IIIa-IV) ovarian cancer of the histologic subtype high grade serous carcinoma (HGSOC) who are going through a diagnostic laparoscopy. They will recieve treatment with a study agent for 10-14 days before surgery. They will be allocated to different study groups according to the diagnostic evaluation performed as standard of care at the department. The study is randomized and unblinded.

The primary investigational agents are:

  1. Metformin tablets, 850 mg x 2 orally.
  2. Acetylsalicylic acid tablets, 160 mg x1 orally
  3. Olaparib capsules, 300 mg x 2 orally
  4. Letrozol tablets, 2.5 mg x 1 orally

Condition or disease Intervention/treatment Phase
Ovarian Cancer Drug: Metformin Drug: Acetylsalicylic acid Drug: Olaparib Drug: Letrozole Early Phase 1

Detailed Description:

The women who agree to participate in the study prior to the laparoscopic evaluation, will be allocated to different study groups according to the diagnostic evaluation performed as standard of care at the department. During inclusion in the first study cohort, the olaparib cohort (n=32), an additional 16 women are randomized as controls and will not receive neither any study drug nor placebo. The study is unblinded. There will not be randomized controls into the other study cohorts, as the control group collected will be utilized as controls for all study agents.

The women in Arm I will be included in the WOO trial, and will be treated with the study agent for 10-14 days prior to tumor reductive surgery, starting the day of laparoscopic surgery (+1 day). The treatment will be discontinued at the time of tumor reductive surgery.

Currently fourmore agents are evaluated as of particular interest, as well as feasible to introduce, in the WOO study set up: metformin, acetylsalicylic acid, olaparib, and letrozol. The first agent listed in the protocol, metformin, will be given to 32 consequtive women, and drug related analyses will thereafter be performed. The next 32 women included in the study will receive the next agent on the list, acetylsalicylic acid, while analyses for the metformin group is ongoing, and after the acetylsalicylic acid study group has been included the next agent on the list is introduced. Should any of the included women be non-eligable to receive one study drug, they will either receive the next agent on the list of the four study drugs, if eligable, or be included as control.

The women in Arm II who agree to participate in the study will not receive the study medication, but standard neoadjuvant chemotherapy until having decreased tumor load radiologically estimated and scheduled for optimal debulking procedure according to standard treatment of this group of patients. Samples from these women will be used as control in the translational part of the where we aim to identify potential molecular pathway(s) and cell type(s) that may be responsible for suboptimal debulking.

During the cancer-directed surgical procedure in participants in both Arms additional tissue samples from matching sites, preferably from tissues removed as part of the operation, as well as blood and urine samples, are obtained for comparative analysis. By use of the collected samples we can evaluate the clinical and molecular impact of the study agents among those triaged to primary cytoreductive surgery. Promising therapeutic targets identified might later be explored separately in one of the consequtive treatment study groups.

After the debulking surgery all women will follow the recommended standard of care, including chemotherapy and consolidating bevacisumab where indicated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 143 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: The first treatment cohort has a randomized design 2:1 (olaparib 32:control 16). The study is unblinded. In the following treatment arms are initiated each will included patients (n=32) will be offered the study-prespecified treatment drug.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: IMPACT: A Phase 0 Randomized Window-of-Opportunity Study of Novel and Repurposed Therapeutic Agents in Women Triaged to Primary Surgery for Advanced Epithelial Ovarian Cancer in Stages IIIa - IV.
Actual Study Start Date : May 4, 2018
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : June 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Ovarian Cancer

Arm Intervention/treatment
No Intervention: Feasibility study cohort
Experimental: Metformin
850 mg
Drug: Metformin
Metformin tablets 850 mg x 2 orally

Experimental: Acetylsalicylic acid
160 mg
Drug: Acetylsalicylic acid
Acetylsalicylic acid tablets 160 mg x1 orally

Experimental: Olaparib
300 mg x 2
Drug: Olaparib
Olaparib capsules 300 mg x 2 orally

Experimental: Letrozol
2.5 mg
Drug: Letrozole
Letrozol tablets 2.5 mg x 1 orally




Primary Outcome Measures :
  1. Changes in the expression of biomarkers [ Time Frame: 3 months ]
    A characterization of the tumor tissues from each patient will be performed (in pair). For each drug a specific biomarker is selected. The changes in expression of the defined biomarkers represent the primary outcome parameters. biomarkers related to the study agents and operability



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have a clinical diagnosis of advanced ovarian, tubal or primary peritoneal cancer. Advanced disease is defined as at least stage 3 ovarian cancer. Definition of stages will be according to the Norwegian guidelines (Norsk Gynekologisk Forening, Veileder i gynekologisk onkologi, Kapittel: Eggstokk-, tube-, bukhinnekreft. Revisjon 01.12.15). If the clinical staff in charge of the patients plan to perform cytoreductive surgery, the patient can participate in the study, irrespective of ECOG performance status. Patients must not have metastases to the central nervous system and/or carcinomatous meningitis.
  2. Age 18 years or above
  3. Primary treatment setting. No prior treatment for gynecological cancer. Women who have been treated surgically for cervical cancer or precancerous lesions on the cervix can be included if she has finished treatment a year or more before current diagnosis of ovarian cancer.
  4. Must have laboratory values as the following :

    • White Blood Cells ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hemoglobin ≥ 9g/dL (≥ 5.6 mmol/L)
    • Creatinine ≤ 140 μmol/L; if creatinine is borderline, the creatinine clearance ≥ 40 mL/min;
    • Bilirubin < 20 % above the upper limit of normal
    • ASAT and ALAT ≤ 2.5 the upper limit of normal
    • Albumin ≥ 2.5 g/L
    • HbA1c < 8.0 %
    • INR < 2.0
  5. All laboratory tests for screening are taken maximum 14 days before start of treatment with study drug.
  6. Ability to understand a written informed consent document, and the willingness to sign it.
  7. Presence of adequate venous accesses for required study blood samples

Exclusion Criteria:

  1. Inability to understand the information given and unable to consent and/or give the information requested, due to language, mental capacity, or disease.
  2. Inability to receive substances per os.
  3. Pregnancy. Pregnant women are excluded from this study, as terapeutic treatment for ovarian cancer includes teratogenic chemotherapy and surgical removal of the uterus and the ovaries.
  4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to investigational drug or its composites.
  5. History of dysregulated coagulation or known bleeding disorder.
  6. Patients known to be Hepatitis B surface antigen positive, who have human immune deficiency virus (HIV) infection, and patients known or suspected to have active Hepatitis C infection.
  7. Patients diagnosed or treated for other malignancy within 1 year of administration of the first dose of the study agent, or previously diagnosed with other malignancy and have residual disease. Patients with non-melanoma skin cancer or any type of carcinoma in situ will not be excluded if they have had a complete tumor resection.
  8. Currently participate or have participated within the last four weeks of the first dose of the study agent in other studies including medication of participants.
  9. Diagnosis of immune deficiency disorder or having received immunosuppressant treatment within the last 7 days before planned intake of the first dose of the study agent. Corticosteroids in physiologic doses can be acceptable.
  10. Histologic diagnosis of non-High grade serous ovarian cancer.
  11. Presence of active tumors in the central nervous system and/or carcinomatous meningitis.
  12. Presence of active infection requiring systemic treatment.
  13. Current diagnosis of bowel obstruction (i.e. ileus or subileus).
  14. Individuals with indication of a condition, treatment or aberrant laboratory results that either can effect the results of this study or the sustainance of participation, such as renal failure stage ≥ 4, heart failure ≥ New York Heart Association (NYHA) grade III, a medical history of severe psychiatric disease, or a current diagnosis of alkoholism or drug addiction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03378297


Contacts
Layout table for location contacts
Contact: Line Bjørge, MD, PhD +47 55975000 line.bjorge@uib.no
Contact: Liv Cecilie V Thomsen, MD, PhD +47 55975000 liv.vestrheim@uib.no

Locations
Layout table for location information
Norway
Helse Bergen HF, Haukeland University Hospital Recruiting
Bergen, Norway, 5021
Contact: Liv Cecilie V Thomsen, MD, PhD    +47 55975000    Liv.Vestrheim@uib.no   
Contact: Line Bjørge, MD, PhD    +47 55975000    line.bjorge@uib.no   
Principal Investigator: Line Bjørge, MD, PhD         
Sub-Investigator: Liv Cecilie V Thomsen, MD, PhD         
Sub-Investigator: Kathrine Woie, MD, PhD         
Sub-Investigator: Bjørn Tore Gjertsen, MD, PhD         
Helse Stavanger HF, Stavanger University Hospital Recruiting
Stavanger, Norway, 4068
Contact: Bent Fiane, MD    +47 51518000    bent.eltvedt.fiane@sus.no   
Contact: Cecilie F Torkildsen, MD    +47 51518000    cecilie.torkildsen@gmail.com   
Principal Investigator: Bent Fiane, MD         
Sub-Investigator: Cecilie F Torkildsen, MD         
Sub-Investigator: Ragnar K Sande, MD, PhD         
Sponsors and Collaborators
Haukeland University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Line Bjørge, MD, PhD Helse-Bergen HF

Layout table for additonal information
Responsible Party: Haukeland University Hospital
ClinicalTrials.gov Identifier: NCT03378297    
Other Study ID Numbers: 2017/1168
First Posted: December 19, 2017    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Haukeland University Hospital:
Ovarian cancer
Phase 0
Window-of-opportunity
Suregry
Repurposing
Metformin
Acetylsalicylic acid
Olaparib
Letrozol
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Aspirin
Metformin
Letrozole
Olaparib
Hypoglycemic Agents
Physiological Effects of Drugs
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Poly(ADP-ribose) Polymerase Inhibitors